Decreased Metabolism in the Cerebral Cortex in Early-Stage Huntington's Disease: A Possible Biomarker of Disease Progression?
- PMID: 23346156
- PMCID: PMC3543905
- DOI: 10.3988/jcn.2013.9.1.21
Decreased Metabolism in the Cerebral Cortex in Early-Stage Huntington's Disease: A Possible Biomarker of Disease Progression?
Abstract
Background and purpose: Huntington's disease (HD) is an autosomal-dominant inherited neurodegenerative disorder. Genetic analysis of abnormal CAG expansion in the IT15 gene allows disease confirmation even in the preclinical stage. However, because there is no treatment to cure or delay the progression of this disease, monitoring of biological markers that predict progression is warranted.
Methods: FDG-PET was applied to 13 patients with genetically confirmed HD in the early stage of the disease. We recorded the initial and follow-up statuses of patients using the Independence Scale (IS) of the Unified Huntington's Disease Rating Scale. The progression rate (PR) was calculated as the annual change in the IS. The patients were divided into two groups with faster and slower progression, using the median value of the PR as the cut-off. FDG-PET data were analyzed using regions of interest, and compared among the two patient groups and 11 age- and sex-matched controls.
Results: The mean CAG repeat size in patients was 44.7. The CAG repeat length was inversely correlated with the age at onset as reported previously, but was not correlated with the clinical PR. Compared with normal controls, hypometabolism was observed even at very early stages of the disease in the bilateral frontal, temporal, and parietal cortices on FDG-PET. The decreases in metabolism in the bilateral frontal, parietal, and right temporal cortices were much greater in the faster-progression group than in the slower-progression group.
Conclusions: A decrease in cortical glucose metabolism is suggested as a predictor for identifying a more rapid form of progression in patients with early-stage HD.
Keywords: FDG-PET; Huntington's disease; biomarker; cortical metabolism; progression.
Conflict of interest statement
The authors have no financial conflicts of interest.
Figures

Similar articles
-
Molecular Imaging Markers to Track Huntington's Disease Pathology.Front Neurol. 2017 Jan 30;8:11. doi: 10.3389/fneur.2017.00011. eCollection 2017. Front Neurol. 2017. PMID: 28194132 Free PMC article. Review.
-
Striatal hypometabolism in premanifest and manifest Huntington's disease patients.Eur J Nucl Med Mol Imaging. 2016 Nov;43(12):2183-2189. doi: 10.1007/s00259-016-3445-y. Epub 2016 Jun 28. Eur J Nucl Med Mol Imaging. 2016. PMID: 27349245
-
Biological and clinical manifestations of juvenile Huntington's disease: a retrospective analysis.Lancet Neurol. 2018 Nov;17(11):986-993. doi: 10.1016/S1474-4422(18)30294-1. Epub 2018 Sep 19. Lancet Neurol. 2018. PMID: 30243861
-
[Importance of the number of trinucleotide repeat expansions in the clinical manifestations of Huntington's chorea].Srp Arh Celok Lek. 1998 Mar-Apr;126(3-4):77-82. Srp Arh Celok Lek. 1998. PMID: 9863360 Serbian.
-
Interrupting sequence variants and age of onset in Huntington's disease: clinical implications and emerging therapies.Lancet Neurol. 2020 Nov;19(11):930-939. doi: 10.1016/S1474-4422(20)30343-4. Lancet Neurol. 2020. PMID: 33098802 Review.
Cited by
-
Current Status of Huntington's Disease in Korea: A Nationwide Survey and National Registry Analysis.J Mov Disord. 2015 Jan;8(1):14-20. doi: 10.14802/jmd.14038. Epub 2015 Jan 13. J Mov Disord. 2015. PMID: 25614781 Free PMC article.
-
Prospects for neuroprotective therapies in prodromal Huntington's disease.Mov Disord. 2014 Mar;29(3):285-93. doi: 10.1002/mds.25835. Epub 2014 Feb 26. Mov Disord. 2014. PMID: 24573776 Free PMC article. Review.
-
Translation of MicroRNA-Based Huntingtin-Lowering Therapies from Preclinical Studies to the Clinic.Mol Ther. 2018 Apr 4;26(4):947-962. doi: 10.1016/j.ymthe.2018.02.002. Epub 2018 Feb 8. Mol Ther. 2018. PMID: 29503201 Free PMC article. Review.
-
Huntington disease: natural history, biomarkers and prospects for therapeutics.Nat Rev Neurol. 2014 Apr;10(4):204-16. doi: 10.1038/nrneurol.2014.24. Epub 2014 Mar 11. Nat Rev Neurol. 2014. PMID: 24614516 Review.
-
Molecular Imaging Markers to Track Huntington's Disease Pathology.Front Neurol. 2017 Jan 30;8:11. doi: 10.3389/fneur.2017.00011. eCollection 2017. Front Neurol. 2017. PMID: 28194132 Free PMC article. Review.
References
-
- Kremer B, Goldberg P, Andrew SE, Theilmann J, Telenius H, Zeisler J, et al. A worldwide study of the Huntington's disease mutation. The sensitivity and specificity of measuring CAG repeats. N Engl J Med. 1994;330:1401–1406. - PubMed
-
- Hersch S, Rosas H, Ferrante R. Neuropathology and pathophysiology of Huntington's disease. New York: McGraw-Hill; 2004.
-
- Hayden MR, Hewitt J, Stoessl AJ, Clark C, Ammann W, Martin WR. The combined use of positron emission tomography and DNA polymorphisms for preclinical detection of Huntington's disease. Neurology. 1987;37:1441–1447. - PubMed
-
- Mazziotta JC, Phelps ME, Pahl JJ, Huang SC, Baxter LR, Riege WH, et al. Reduced cerebral glucose metabolism in asymptomatic subjects at risk for Huntington's disease. N Engl J Med. 1987;316:357–362. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials